Minakem-flap
Minakem-flap

Find Clinical Drug Pipeline Developments & Deals by Biond Biologics

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Therapeutic Area filter
    Study Phase filter
      Country filter
        News Type filter
          Company filter
            refresh

            Companies By Therapeutic Area Full Screen

            Development Status Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): BND-22

            Therapeutic Area: Oncology Product Name: BND-22

            Highest Development Status: IND Enabling Product Type: Large molecule

            Partner/Sponsor/Collaborator: Sanofi

            Deal Size: $1,125.0 million Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement January 12, 2021

            Details:

            BND-22 is a humanized IgG4, antagonist antibody targeting the Ig-like transcript 2 (ILT2) receptor in development for the treatment of solid tumors.